Drugs / DF2156A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01571895 | Feb → Jul 2012 | bullous pemphigoid | Dompé Farmaceutici S.p.A | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DF2156A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01571895 ↗ |
| Modality | Small molecule | “DF2156A is a novel small molecule” NCT01571895 ↗ |
| Route | Oral | “receive DF2156A orally” NCT01571895 ↗ |